Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» MK-1308
MK-1308
Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?
Endpoints
Fri, 06/9/17 - 11:13 am
Merck
anti-PD-L1
Keytruda
MK-1308
Bristol-Myers Squibb